Patient Engagement Using New Technology to Improve Adherence to Positive Airway Pressure Therapy: A Retrospective Analysis
Overview
Affiliations
Background: Sleep apnea has major neurocognitive and cardiovascular and metabolic risks. Treatment of sleep apnea is suboptimal because of variable adherence to existing therapies.
Methods: This trial compared positive airway pressure adherence among patients who were provided active patient engagement (APE) technology vs those who received usual care monitoring (UCM). The primary outcome was expressed by using the US Medicare definition of adherence. Adherence data from two cloud-based databases (AirView and myAir) were analyzed for patients with sleep apnea. Data were included if a patient's activation date in the APE tool was within 7 days of the therapy start date in the UCM database during a defined time window. Data were propensity matched in a 1:2 ratio (APE:UCM) based on baseline patient characteristics.
Results: A total of 128,037 patients were analyzed. Baseline characteristics were typical of a sleep clinic cohort. APE was associated with more patients achieving adherence criteria (87.3%) compared with UCM patients (70.4%; P < .0001 for the difference). Average therapy usage was 5.9 h per night in the APE group vs 4.9 h per night in the matched UCM patients (P < .0001). Patients with sleep apnea "struggling" with therapy adherence had a 17.6% absolute improvement in adherence using APE compared with UCM.
Conclusions: Robust therapy adherence rates can be achieved by adding modern technology to usual care. Adopting advances in technology in care management may allow clinicians to more effectively and efficiently treat patients who have sleep apnea. Rigorous randomized controlled trials may be required before making strong clinical recommendations.
Digital health delivery in respiratory medicine: adjunct, replacement or cause for division?.
Ottewill C, Gleeson M, Kerr P, Hale E, Costello R Eur Respir Rev. 2024; 33(173).
PMID: 39322260 PMC: 11423130. DOI: 10.1183/16000617.0251-2023.
Novel concept of personalized therapy with continuous positive airway pressure.
Yamauchi M, Moritsuchi Y, Hamada E Sleep Breath. 2024; 28(5):1863-1865.
PMID: 38951384 PMC: 11450021. DOI: 10.1007/s11325-024-03095-0.
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance.
Harding C, Fuentes A, Malhotra A Expert Opin Pharmacother. 2024; 25(8):1019-1026.
PMID: 38913403 PMC: 11227253. DOI: 10.1080/14656566.2024.2365329.
Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis.
Malhotra A, Heilmann C, Banerjee K, Dunn J, Bunck M, Bednarik J Sleep Med. 2024; 121:26-31.
PMID: 38908268 PMC: 11330732. DOI: 10.1016/j.sleep.2024.06.014.
Continuous positive airway pressure is here to stay.
Malhotra A, Pettus J Lancet Respir Med. 2024; 12(7):507-508.
PMID: 38768623 PMC: 11211046. DOI: 10.1016/S2213-2600(23)00469-1.